Jacob Sands, MD, Dana-Farber Cancer Institute
Articles by Jacob Sands, MD, Dana-Farber Cancer Institute
Novel Treatment Approaches for SCLC and Future Perspectives
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
2L Dosing Considerations and Management Strategies for SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
LAGOON and IMFORTE Trials: Data Updates and Expert Insights
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.
Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.
ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.
Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists discuss long-term data updates from the CASPIAN trial and the associated implications on clinical practice.
Expert Insights on First-line Treatment Strategies in SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.
Evolving Role of Biomarkers in SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.
Impact of Disease Staging on Prognosis and Treatment in SCLC
ByTaofeek K. Owonikoko, MD, PhD,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.
Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer
ByTaofeek K. Owonikoko, MD, PhD,Anne Chiang, MD, PhD, Yale Cancer Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.
NSCLC: Final Thoughts
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology The discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.
NSCLC: Overcoming Challenges
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).
ROS1-Rearranged NSCLC: Updates FromASCO
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.
Preferred Treatment for ALK-Rearranged NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).
ALK-Rearranged NSCLC: Updates From ASCO
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).
RET-Fusions in NSCLC: Updates From ASCO
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).
Recent FDA-Approvals: MET Exon 14 Mutations in NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.
Recent FDA-Approvals: HER2-Mutated NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.
NSCLC: Sotorasib in Practice
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).
Recent FDA-Approvals: KRAS G12C-Mutated NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).
ASCO 2021: New Data for NSCLC Treatment Options
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).
NSCLC: EGFR Exon 20 Insertion Treatment Options
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .
Implications of Novel NSCLC Targeted Therapies
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.
Novel Therapies for NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.
NSCLC: FLAURA Trial Results
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Edward Kim, MD, briefly summarizes results from the FLAURA trial in the treatment of previously untreated EGFR+ advanced non–small cell lung cancer (NSCLC).
CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes
ROS1-Rearranged NSCLC: Updates FromASCO
RET-Fusions in NSCLC: Updates From ASCO